Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis

Jana Lizrova Preiningerova; Marta Vachova

doi:10.1177/1756285616671887

Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis

Ther Adv Neurol Disord. 2017 Jan;10(1):67-75. doi: 10.1177/1756285616671887. Epub 2016 Oct 19.

Authors

Jana Lizrova Preiningerova¹, Marta Vachova²

Affiliations

¹ Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Praha 2, Praha, 121 08, Czech Republic.
² Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, Faculty of Medicine and General University Hospital in Prague, Praha, Czech Republic.

Abstract

Daclizumab is a humanized monoclonal antibody that binds to the α subunit (CD25) of the interleukin-2 receptor and favorably modulates the immune environment in multiple sclerosis (MS). Blockage of CD25, among other effects, causes expansion and enhanced function of regulatory CD56^bright natural killer cells, which seems to be the leading mechanism of action in MS. Phase II and III clinical trials have demonstrated that monthly subcutaneous injections of daclizumab high yield process (DAC HYP) 150 mg in patients with relapsing MS led to a significant reduction of annualized relapse rate and decreased number of contrast-enhanced lesions on brain magnetic resonance imaging. Treatment with DAC HYP had efficacy superior to treatment with weekly injections of interferon β1a. This review summarizes the development of and clinical experience with daclizumab in MS.

Keywords: CD25; daclizumab; interleukin 2; multiple sclerosis.

Publication types

Review